Afamelanotide

Scenesse, Melanotan I

Grade A: Approved and proven

TL;DR: Afamelanotide (Scenesse) is FDA-approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder. Approval was based on controlled Phase 3 trials demonstrating significantly greater time outdoors without phototoxic pain compared to placebo. The drug is administered as a subcutaneous implant containing 16 mg every two months and is restricted to adults; pediatric safety and efficacy have not been established. Evidence for afamelanotide is robust within its narrow approved indication; evidence for any other use, including cosmetic tanning, is not FDA-supported and any such use lacks rigorous safety evaluation.

Key Takeaways

Grade A: Approved and proven
FDA approved: FDA-approved (2019) for adult EPP patients to increase pain-free light exposure; not approved for any cosmetic or other indication.
Compounding: Afamelanotide is FDA-approved only as Scenesse (subcutaneous implant) for adult EPP patients; it is not approved for cosmetic tanning or any other purpose. Compounding is restricted because an approved product exists. Non-pharmaceutical afamelanotide sold for tanning has no regulatory oversight.

Afamelanotide chemical structure — Structure via PubChem CID 16197727

Mechanism

Afamelanotide is a potent, long-acting melanocortin-1 receptor (MC1R) agonist that stimulates constitutive melanin synthesis in skin, increasing photoprotective pigmentation.

Evidence

Afamelanotide (Scenesse) is FDA-approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder. Approval was based on controlled Phase 3 trials demonstrating significantly greater time outdoors without phototoxic pain compared to placebo. The drug is administered as a subcutaneous implant containing 16 mg every two months and is restricted to adults; pediatric safety and efficacy have not been established. Evidence for afamelanotide is robust within its narrow approved indication; evidence for any other use, including cosmetic tanning, is not FDA-supported and any such use lacks rigorous safety evaluation.

Safety and risks

Nausea (19% afamelanotide vs. 14% placebo) and oropharyngeal pain (7% vs. 5% placebo) are among the most common adverse reactions documented in FDA labeling. Implant site reactions occurred in 21% of patients versus 10% with placebo. Diffuse skin hyperpigmentation occurs frequently due to MC1R-mediated melanin synthesis and was reported in the majority of patients; this is a systemic effect affecting the skin broadly and is distinct from implant site reactions. Melanocytic nevus (mole) formation or changes in existing nevi have been reported, and any new or changing pigmented lesion should be evaluated by a dermatologist. Vitamin D status may be altered in EPP patients using afamelanotide, as increased sun tolerance can reduce the behavioral avoidance that previously limited UV exposure. Use of unregulated afamelanotide from non-pharmaceutical sources for cosmetic tanning purposes carries unknown risks of infection, immune reactions, and long-term nevi or pigmentation changes, with no safety data from controlled studies.

Interactions

No specific drug-drug interactions are characterized in the FDA label; patients should be monitored for additive hyperpigmentation if receiving other melanocortin-active agents.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

Afamelanotide is FDA-approved only as Scenesse (subcutaneous implant) for adult EPP patients; it is not approved for cosmetic tanning or any other purpose. Compounding is restricted because an approved product exists. Non-pharmaceutical afamelanotide sold for tanning has no regulatory oversight.

Sources

Afamelanotide is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).